Assessment of Maraviroc Exposure–Response Relationship at 48 Weeks in Treatment-Experienced HIV-1–Infected Patients in the MOTIVATE Studies
Abstract: Efficacy exposure–response relationships of the CCR5 antagonist maraviroc were evaluated across two phase III clinical trials. This post-hoc analysis used 48-week efficacy data from 841 treatment-experienced patients infected with CCR5-tropic human immunodeficiency virus type 1 (HIV-1), identified by the enhanced sensitivity Trofile assay. Probability of treatment success (viral RNA
Full Reference: Jacqmin, P., J. R. Wade, B. Weatherley, E. Snoeck, S. Marshall, and L. McFadyen. “Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.” CPT: Pharmacometrics & Systems Pharmacology 2 (August 14, 2013): e64. doi:10.1038/psp.2013.42.
Link to full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3828006/